scholarly article | Q13442814 |
P50 | author | Steven C. Almo | Q28197196 |
Alessandro Sette | Q28324161 | ||
Cecilia S. Lindestam Arlehamn | Q42893016 | ||
Steven A Porcelli | Q62032714 | ||
Scott J Garforth | Q96687812 | ||
P2093 | author name string | John Chan | |
William R Jacobs | |||
Alison J Johnson | |||
Jiayong Xu | |||
Steven C Kennedy | |||
Sushma Bharrhan | |||
P2860 | cites work | Allergenicity of mycobacterial ribosomal and ribonucleic acid preparations in mice and guinea pigs | Q24649093 |
Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model | Q24675231 | ||
TB vaccine development and the End TB Strategy: importance and current status. | Q26748621 | ||
Recent advances in the development of vaccines for tuberculosis | Q26796440 | ||
UCSF Chimera--a visualization system for exploratory research and analysis | Q27860666 | ||
MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods | Q27860929 | ||
Current efforts and future prospects in the development of live mycobacteria as vaccines | Q28087077 | ||
Structome analysis of virulent Mycobacterium tuberculosis, which survives with only 700 ribosomes per 0.1 fl of cytoplasm | Q28543142 | ||
The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity | Q28727776 | ||
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial | Q29620144 | ||
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics | Q33218340 | ||
A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach | Q33326976 | ||
The antituberculosis antibiotic capreomycin inhibits protein synthesis by disrupting interaction between ribosomal proteins L12 and L10. | Q33622886 | ||
Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis. | Q33791961 | ||
Outcome of tuberculosis treatment and its predictors among HIV infected patients in southwest Ethiopia | Q33806776 | ||
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults | Q33950119 | ||
Measurement of the rates of synthesis of three components of ribosomes of Mycobacterium fortuitum: a theoretical approach to qRT-PCR experimentation | Q33996232 | ||
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis | Q34146613 | ||
Variation in protection by BCG: implications of and for heterologous immunity | Q34288541 | ||
Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature | Q34349749 | ||
Comparing genomes within the species Mycobacterium tuberculosis | Q35033207 | ||
A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis | Q35033838 | ||
ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination | Q35069386 | ||
Effect of Trypsin and Ribonuclease on the Immunogenic Activity of Ribosomes and Ribonucleic Acid Isolated from Mycobacterium tuberculosis | Q35181452 | ||
A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis | Q35647253 | ||
Immune epitope database analysis resource | Q36088427 | ||
Ribosome hibernation facilitates tolerance of stationary-phase bacteria to aminoglycosides | Q36158256 | ||
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial | Q36287555 | ||
Identification of antituberculosis agents that target ribosomal protein interactions using a yeast two-hybrid system | Q36378532 | ||
Structure of Ribosomal Silencing Factor Bound to Mycobacterium tuberculosis Ribosome | Q36478960 | ||
M. tuberculosis T Cell Epitope Analysis Reveals Paucity of Antigenic Variation and Identifies Rare Variable TB Antigens | Q36594099 | ||
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations | Q36628376 | ||
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial. | Q36888036 | ||
IMMUNOGENIC ACTIVITY OF A RIBOSOMAL FRACTION OBTAINED FROM MYCOBACTERIUM TUBERCULOSIS. | Q37419107 | ||
An expression vector tailored for large-scale, high-throughput purification of recombinant proteins | Q37471293 | ||
Evasion and subversion of antigen presentation by Mycobacterium tuberculosis | Q37534913 | ||
The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: part I: the origins and nature of the problem | Q37700331 | ||
The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: Part II: scientific advances that may provide solutions | Q37742687 | ||
First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses | Q37823094 | ||
The immunological life cycle of tuberculosis | Q38025869 | ||
The balance between protective and pathogenic immune responses in the TB-infected lung | Q38293027 | ||
Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: A five-year review | Q38627028 | ||
Mycobacterium tuberculosis infection and vaccine development. | Q38828636 | ||
The burden of HIV on Tuberculosis patients in the Volta region of Ghana from 2012 to 2015: implication for Tuberculosis control | Q39445754 | ||
Comparison of several culture media used for studies on mycobacteriophages (Plates XII-XIV) | Q39601879 | ||
Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis | Q39842246 | ||
Identification of Mycobacterial RplJ/L10 and RpsA/S1 Proteins as Novel Targets for CD4+ T Cells | Q40361036 | ||
Mechanism and rates of exchange of L7/L12 between ribosomes and the effects of binding EF-G. | Q40744224 | ||
Status of vaccine research and development of vaccines for tuberculosis | Q40757121 | ||
Reprogramming the T Cell Response to Tuberculosis | Q40829662 | ||
Demonstration in tissue culture of lymphocyte-mediated immunity to tuberculosis. | Q40884282 | ||
Zinc regulates a switch between primary and alternative S18 ribosomal proteins in Mycobacterium tuberculosis | Q41096097 | ||
First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults | Q41148040 | ||
Tuberculosis vaccines: time for a global strategy | Q41463414 | ||
Ribosome degradation in growing bacteria | Q41945677 | ||
Protective CD4 T cells targeting cryptic epitopes of Mycobacterium tuberculosis resist infection-driven terminal differentiation | Q42226870 | ||
The dormancy regulator DosR controls ribosome stability in hypoxic mycobacteria. | Q42227117 | ||
Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells | Q42262934 | ||
IFNγ/TNFα specific-cells and effector memory phenotype associate with active tuberculosis | Q42272434 | ||
The Complete Structure of the Mycobacterium smegmatis 70S Ribosome. | Q50904778 | ||
Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen | Q57100109 | ||
Dominant TNF-α+ Mycobacterium tuberculosis–specific CD4+ T cell responses discriminate between latent infection and active disease | Q58074694 | ||
The relationship between sedimentation value and immunogenic acitivity of mycobacterial ribonucleic acid | Q69380568 | ||
Host immune responses to ribosome, ribosomal proteins, and RNA from Mycobacterium bovis bacille de Calmette-Gúerin | Q78164042 | ||
The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans | Q84197648 | ||
HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality | Q84734382 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | immunology | Q101929 |
parasitology | Q180502 | ||
infectious disease | Q18123741 | ||
P577 | publication date | 2018-09-01 | |
P1433 | published in | Infection and Immunity | Q6029193 |
P1476 | title | Identification of Mycobacterial Ribosomal Proteins as Targets for CD4 T Cells That Enhance Protective Immunity in Tuberculosis | |
P478 | volume | 86 |
Q59800431 | A Review on T Cell Epitopes Identified Using Prediction and Cell-Mediated Immune Models for Mycobacterium tuberculosis and Bordetella pertussis | cites work | P2860 |
Search more.